Loading organizations...
§ Private Profile · Saint Louis, MO, USA
Diagnostic test developer creating noninvasive tests for gastrointestinal health using seRNA biomarkers, focused on colorectal cancer screening.
Geneoscopy has raised $216.9M across 3 funding rounds.
Key people at Geneoscopy.
Geneoscopy has raised $216.9M in total across 3 funding rounds.
Geneoscopy is a St. Louis, Missouri-based medical diagnostics company that develops noninvasive screening tests for gastrointestinal health utilizing stool-derived eukaryotic RNA biomarkers. The organization operates an 11,000-square-foot laboratory and office facility, currently employing a dedicated team of 50 professionals to support its ongoing clinical and commercial operations. Its lead product is a colorectal cancer screening test designed to detect precancerous adenomas, which recently completed a comprehensive 10,000-patient clinical trial known as CRC-PREVENT. The company has secured Breakthrough Device Designation from the FDA and maintains a CLIA-certified laboratory environment to process its proprietary diagnostic assays prior to Premarket Approval. The underlying diagnostic technology was developed in conjunction with research conducted at the Washington University School of Medicine to provide alternatives to traditional colonoscopies. Geneoscopy was originally founded in 2015 by Andrew Barnell and Erica Barnell.
Geneoscopy has raised $216.9M across 3 funding rounds. Most recently, it raised $105.0M Series C in January 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 8, 2025 | $105M Series C | BIO RAD Laboratories | — | Announced |
| Nov 17, 2021 | $105M Series B | — | — | Announced |
| Oct 2, 2019 | $6.9M Series A | Cultivation Capital, NT Investments | — | Announced |
Key people at Geneoscopy.
Geneoscopy has raised $216.9M in total across 3 funding rounds.
Geneoscopy's investors include Bio-Rad Laboratories, Cultivation Capital, NT Investments.
